To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses
Abstract
:Conflicts of Interest
References and Notes
- Williamson, J. Dragon’s Island; Simon and Schuster: New York, NY, USA, 1951. [Google Scholar]
- Goodman, A. Intuition: A Novel; Dial Press: New York, NY, USA, 2006. [Google Scholar]
- Grey’s Anatomy. Where the Wild Things Are; Copyright Collection (Library of Congress); 2008. [Google Scholar]
- Lawrence, F.; Goldsman, A.; Lassiter, J.; Heyman, D.; Moritz, N.H.; Protosevich, M.; Smith, W.; Braga, A.; Mihok, D.; Matheson, R.; et al. Pictures (1969- ), Village Roadshow Pictures., Weed Road Pictures., Overbrook Films., Copyright Collection (Library of Congress). I am legend. United States: Warner Bros. Pictures; 2007. p 11 film reels of 11 on 16 (ca. 100 min., ca. 109,000 ft.).
- Egan, D. House versus God. Fox Television Series “House” 2006; Season 2, Episode 19.
- Levaditi, C.; Nicolau, S. Sur la culture de virus vaccinal dans les neoplasmes epitheliaux. CR Soc. Biol. 1922, 86, 928. (In French) [Google Scholar]
- Levaditi, C.; Nicolau, S. Affinite du virus herpetique pour les neoplasmes epitheliaux. CR Soc. Biol. 1922, 87, 498–500. (In French) [Google Scholar]
- Moore, A. Viruses with oncolytic properties and their adaptation to tumors. Ann. N. Y. Acad. Sci. 1952, 54, 945–952. [Google Scholar] [CrossRef] [PubMed]
- Moore, A.E. The destructive effect of the virus of Russian Far East encephalitis on the transplantable mouse sarcoma 180. Cancer 1949, 2, 525–534. [Google Scholar] [CrossRef]
- Moore, A.E.; O’Connor, S. Further studies on the destructive effect of the virus of Russian Far East encephalitis on the transplantable mouse sarcoma 180. Cancer 1950, 3, 886–890. [Google Scholar] [CrossRef]
- Moore, A.E. Enhancement of oncolytic effect of Russian encephalitis virus. Proc. Soc. Exp. Biol. Med. 1951, 76, 749–754. [Google Scholar] [CrossRef] [PubMed]
- Moore, A.E. Inhibition of growth of five transplantable mouse tumors by the virus of Russian Far East encephalitis. Cancer 1951, 4, 375–382. [Google Scholar] [CrossRef]
- Bennett, J.J.; Kooby, D.A.; Delman, K.; McAuliffe, P.; Halterman, M.W.; Federoff, H.; Fong, Y. Antitumor efficacy of regional oncolytic viral therapy for peritoneally disseminated cancer. J. Mol. Med. 2000, 78, 166–174. [Google Scholar] [CrossRef] [PubMed]
- Stanziale, S.F.; Petrowsky, H.; Joe, J.K.; Roberts, G.D.; Zager, J.S.; Gusani, N.J.; Ben-Porat, L.; Gonen, M.; Fong, Y. Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase. Surgery 2002, 132, 353–359. [Google Scholar] [CrossRef] [PubMed]
- Cody, J.J.; Markert, J.M.; Hurst, D.R. Histone deacetylase inhibitors improve the replication of oncolytic herpes simplex virus in breast cancer cells. PLoS ONE 2014, 9, e92919. [Google Scholar] [CrossRef] [PubMed]
- Israelsson, S.; Savneby, A.; Ekstrom, J.O.; Jonsson, N.; Edman, K.; Lindberg, A.M. Improved replication efficiency of echovirus 5 after transfection of colon cancer cells using an authentic 5' RNA genome end methodology. Invest. New Drugs 2014, 32, 1063–1070. [Google Scholar] [CrossRef] [PubMed]
- Toda, M.; Rabkin, S.D.; Kojima, H.; Martuza, R.L. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum. Gene Ther. 1999, 10, 385–393. [Google Scholar] [CrossRef] [PubMed]
- Benencia, F.; Courreges, M.C.; Fraser, N.W.; Coukos, G. Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation. Cancer Biol. Ther. 2008, 7, 1194–1205. [Google Scholar] [CrossRef] [PubMed]
- Andtbacka, R.H.; Kaufman, H.L.; Collichio, F.; Amatruda, T.; Senzer, N.; Chesney, J.; Delman, K.A.; Spitler, L.E.; Puzanov, I.; Agarwala, S.S.; et al. Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 2015, 33, 2780–2788. [Google Scholar] [CrossRef] [PubMed]
- Marques, C.P.; Hu, S.; Sheng, W.; Cheeran, M.C.; Cox, D.; Lokensgard, J.R. Interleukin-10 attenuates production of HSV-induced inflammatory mediators by human microglia. Glia 2004, 47, 358–366. [Google Scholar] [CrossRef] [PubMed]
- Miller, C.G.; Fraser, N.W. Role of the immune response during neuro-attenuated herpes simplex virus-mediated tumor destruction in a murine intracranial melanoma model. Cancer Res. 2000, 60, 5714–5722. [Google Scholar] [PubMed]
- Ali, S.; King, G.D.; Curtin, J.F.; Candolfi, M.; Xiong, W.; Liu, C.; Puntel, M.; Cheng, Q.; Prieto, J.; Ribas, A.; et al. Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res. 2005, 65, 7194–7204. [Google Scholar] [CrossRef] [PubMed]
- Kennedy, B.C.; Maier, L.M.; D’Amico, R.; Mandigo, C.E.; Fontana, E.J.; Waziri, A.; Assanah, M.C.; Canoll, P.; Anderson, R.C.; Anderson, D.E.; et al. Dynamics of central and peripheral immunomodulation in a murine glioma model. BMC Immunol. 2009, 10. [Google Scholar] [CrossRef] [PubMed]
- Contardi, E.; Palmisano, G.L.; Tazzari, P.L.; Martelli, A.M.; Fala, F.; Fabbi, M.; Kato, T.; Lucarelli, E.; Donati, D.; Polito, L.; et al. CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int. J. Cancer 2005, 117, 538–550. [Google Scholar] [CrossRef] [PubMed]
- Weber, J. Immune checkpoint proteins: A new therapeutic paradigm for cancer—Preclinical background: CTLA-4 and PD-1 blockade. Semin. Oncol. 2010, 37, 430–439. [Google Scholar] [CrossRef] [PubMed]
- Chiocca, E.A. The host response to cancer virotherapy. Curr. Opin. Mol. Ther. 2008, 10, 38–45. [Google Scholar] [PubMed]
- Cobbs, C.S. Evolving evidence implicates cytomegalovirus as a promoter of malignant glioma pathogenesis. Herpesviridae 2011, 2. [Google Scholar] [CrossRef] [PubMed]
- Friedman, G.K.; Beierle, E.A.; Gillespie, G.Y.; Markert, J.M.; Waters, A.M.; Chen, C.Y.; Denton, N.L.; Haworth, K.B.; Hutzen, B.; Leddon, J.L.; et al. Pediatric cancer gone viral. Part II: Potential clinical application of oncolytic herpes simplex virus-1 in children. Mol. Ther. Oncolytics 2015, 2. [Google Scholar] [CrossRef] [PubMed]
- Huang, J.H.; Zhang, S.N.; Choi, K.J.; Choi, I.K.; Kim, J.H.; Lee, M.G.; Kim, H.; Yun, C.O. Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL. Mol. Ther. 2010, 18, 264–274. [Google Scholar] [CrossRef] [PubMed]
- Beug, S.T.; Tang, V.A.; LaCasse, E.C.; Cheung, H.H.; Beauregard, C.E.; Brun, J.; Nuyens, J.P.; Earl, N.; St-Jean, M.; Holbrook, J.; et al. Smac mimetics and innate immune stimuli synergize to promote tumor death. Nat. Biotechnol. 2014, 32, 182–190. [Google Scholar] [CrossRef] [PubMed]
- Yang, Y.; Xu, H.; Huang, W.; Ding, M.; Xiao, J.; Yang, D.; Li, H.; Liu, X.Y.; Chu, L. Targeting lung cancer stem-like cells with TRAIL gene armed oncolytic adenovirus. J. Cell. Mol. Med. 2015, 19, 915–923. [Google Scholar] [CrossRef] [PubMed]
- Maisonneuve, C.; Bertholet, S.; Philpott, D.J.; de Gregorio, E. Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants. Proc. Natl. Acad. Sci. USA 2014, 111, 12294–12299. [Google Scholar] [CrossRef] [PubMed]
- Medzhitov, R. Recognition of microorganisms and activation of the immune response. Nature 2007, 449, 819–826. [Google Scholar] [CrossRef] [PubMed]
- Hoebe, K.; Janssen, E.; Beutler, B. The interface between innate and adaptive immunity. Nat. Immunol. 2004, 5, 971–974. [Google Scholar] [CrossRef] [PubMed]
- Scheiermann, J.; Klinman, D.M. Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer. Vaccine 2014, 32, 6377–6389. [Google Scholar] [CrossRef] [PubMed]
- Shimeld, C.; Whiteland, J.L.; Williams, N.A.; Easty, D.L.; Hill, T.J. Cytokine production in the nervous system of mice during acute and latent infection with herpes simplex virus type 1. J. Gen. Virol. 1997, 78, 3317–3325. [Google Scholar] [CrossRef] [PubMed]
- Melchjorsen, J.; Sorensen, L.N.; Paludan, S.R. Expression and function of chemokines during viral infections: From molecular mechanisms to in vivo function. J. Leukoc. Biol. 2003, 74, 331–343. [Google Scholar] [CrossRef] [PubMed]
- Thapa, M.; Welner, R.S.; Pelayo, R.; Carr, D.J. CXCL9 and CXCL10 expression are critical for control of genital herpes simplex virus type 2 infection through mobilization of HSV-specific CTL and NK cells to the nervous system. J. Immunol. 2008, 180, 1098–1106. [Google Scholar] [CrossRef] [PubMed]
- Wickham, S.; Lu, B.; Ash, J.; Carr, D.J. Chemokine receptor deficiency is associated with increased chemokine expression in the peripheral and central nervous systems and increased resistance to herpetic encephalitis. J. Neuroimmunol. 2005, 162, 51–59. [Google Scholar] [CrossRef] [PubMed]
- Wuest, T.R.; Thapa, M.; Zheng, M.; Carr, D.J. CXCL10 expressing hematopoietic-derived cells are requisite in defense against HSV-1 infection in the nervous system of CXCL10 deficient mice. J. Neuroimmunol. 2011, 234, 103–108. [Google Scholar] [CrossRef] [PubMed]
- Aghi, M.; Chou, T.C.; Suling, K.; Breakefield, X.O.; Chiocca, E.A. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res. 1999, 59, 3861–3865. [Google Scholar] [PubMed]
- Parker, J.N.; Gillespie, G.Y.; Love, C.E.; Randall, S.; Whitley, R.J.; Markert, J.M. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc. Natl. Acad. Sci. USA 2000, 97, 2208–2213. [Google Scholar] [CrossRef] [PubMed]
- Parker, J.N.; Meleth, S.; Hughes, K.B.; Gillespie, G.Y.; Whitley, R.J.; Markert, J.M. Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12. Cancer Gene Ther. 2005, 12, 359–368. [Google Scholar] [CrossRef] [PubMed]
- Ino, Y.; Saeki, Y.; Fukuhara, H.; Todo, T. Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy. Clin. Cancer Res. 2006, 12, 643–652. [Google Scholar] [CrossRef] [PubMed]
- Lee, K.C.; Hamstra, D.A.; Bullarayasamudram, S.; Bhojani, M.S.; Moffat, B.A.; Dornfeld, K.J.; Ross, B.D.; Rehemtulla, A. Fusion of the HSV-1 tegument protein vp22 to cytosine deaminase confers enhanced bystander effect and increased therapeutic benefit. Gene Ther. 2006, 13, 127–137. [Google Scholar] [CrossRef] [PubMed]
- Wong, R.J.; Patel, S.G.; Kim, S.; DeMatteo, R.P.; Malhotra, S.; Bennett, J.J.; St-Louis, M.; Shah, J.P.; Johnson, P.A.; Fong, Y. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Hum. Gene Ther. 2001, 12, 253–265. [Google Scholar] [CrossRef] [PubMed]
- Zhang, W.; Fulci, G.; Wakimoto, H.; Cheema, T.A.; Buhrman, J.S.; Jeyaretna, D.S.; Stemmer-Rachamimov, A.O.; Rabkin, S.D.; Martuza, R.L. Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models. Neoplasia 2013, 15, 591–599. [Google Scholar] [CrossRef] [PubMed]
- Meisen, W.H.; Kaur, B. How can we trick the immune system into overcoming the detrimental effects of oncolytic viral therapy to treat glioblastoma? Expert Rev. Neurother. 2013, 13, 341–343. [Google Scholar] [CrossRef] [PubMed]
- Roth, J.C.; Cassady, K.A.; Cody, J.J.; Parker, J.N.; Price, K.H.; Coleman, J.M.; Peggins, J.O.; Noker, P.E.; Powers, N.W.; Grimes, S.D.; et al. Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates. Hum. Gene Ther. Clin. Dev. 2014, 25, 16–27. [Google Scholar] [CrossRef] [PubMed]
- Cheema, T.A.; Wakimoto, H.; Fecci, P.E.; Ning, J.; Kuroda, T.; Jeyaretna, D.S.; Martuza, R.L.; Rabkin, S.D. Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proc. Natl. Acad. Sci. USA 2013, 110, 12006–12011. [Google Scholar] [CrossRef] [PubMed]
- Choi, I.K.; Lee, J.S.; Zhang, S.N.; Park, J.; Sonn, C.H.; Lee, K.M.; Yun, C.O. Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rβ2 or IL-18Rα. Gene Ther. 2011, 18, 898–909. [Google Scholar] [CrossRef] [PubMed]
- Andreansky, S.; He, B.; van Cott, J.; McGhee, J.; Markert, J.M.; Gillespie, G.Y.; Roizman, B.; Whitley, R.J. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther. 1998, 5, 121–130. [Google Scholar] [CrossRef] [PubMed]
- Tan, D.Q.; Zhang, L.; Ohba, K.; Ye, M.; Ichiyama, K.; Yamamoto, N. Macrophage response to oncolytic paramyxoviruses potentiates virus-mediated tumor cell killing. Eur. J. Immunol. 2016. [Google Scholar] [CrossRef] [PubMed]
- Vassilev, L.; Ranki, T.; Joensuu, T.; Jager, E.; Karbach, J.; Wahle, C.; Partanen, K.; Kairemo, K.; Alanko, T.; Turkki, R.; et al. Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8 T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer. Oncoimmunology 2015, 4. [Google Scholar] [CrossRef] [PubMed]
- Gil, M.; Komorowski, M.P.; Seshadri, M.; Rokita, H.; McGray, A.J.; Opyrchal, M.; Odunsi, K.O.; Kozbor, D. CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells. J. Immunol. 2014, 193, 5327–5337. [Google Scholar] [CrossRef] [PubMed]
- Chahlavi, A.; Rabkin, S.; Todo, T.; Sundaresan, P.; Martuza, R. Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice. Gene Ther. 1999, 6, 1751–1758. [Google Scholar] [CrossRef] [PubMed]
- Yoon, S.S.; Nakamura, H.; Carroll, N.M.; Bode, B.P.; Chiocca, E.A.; Tanabe, K.K. An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB J. 2000, 14, 301–311. [Google Scholar] [PubMed]
- Miller, C.G.; Fraser, N.W. Requirement of an integrated immune response for successful neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma model. Mol. Ther. 2003, 7, 741–747. [Google Scholar] [CrossRef]
- Smith, T.T.; Cassady, K.A.; Chen, D.; Coleman Clements, J.; Harris, D.C.; Gaston, D.; Crowley, M.; Whitley, R.J.; Markert, J.M. Gene expression profiles after G207 HSV intratumoral infusion: Immune activation in immunocompromised subjects with recurrent glioblastoma. Manuscript in preparation. 2016. [Google Scholar]
- Wang, P.Y.; Swain, H.M.; Kunkler, A.L.; Chen, C.Y.; Hutzen, B.J.; Arnold, M.A.; Streby, K.A.; Collins, M.H.; Dipasquale, B.; Stanek, J.R.; et al. Neuroblastomas vary widely in their sensitivities to herpes simplex virotherapy unrelated to virus receptors and susceptibility. Gene Ther. 2015. [Google Scholar] [CrossRef] [PubMed]
- Kleijn, A.; Kloezeman, J.; Treffers-Westerlaken, E.; Fulci, G.; Leenstra, S.; Dirven, C.; Debets, R.; Lamfers, M. The therapeutic efficacy of the oncolytic virus Delta24-RGD in a murine glioma model depends primarily on antitumor immunity. Oncoimmunology 2014, 3. [Google Scholar] [CrossRef] [PubMed]
- Leddon, J.L.; Chen, C.-Y.; Currier, M.A.; Wang, P.-Y.; Jung, F.A.; Denton, N.L.; Cripe, K.M.; Haworth, K.B.; Arnold, M.A.; Gross, A.C.; et al. Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity. Mol. Ther. Oncolytics 2015, 1. [Google Scholar] [CrossRef]
- Kastrukoff, L.F.; Lau, A.S.; Thomas, E.E. The effect of mouse strain on herpes simplex virus type 1 (HSV-1) infection of the central nervous system (CNS). Herpesviridae 2012, 3, 1–14. [Google Scholar] [CrossRef] [PubMed]
- Halford, W.P.; Balliet, J.W.; Gebhardt, B.M. Re-evaluating natural resistance to herpes simplex virus type 1. J. Virol. 2004, 78, 10086–10095. [Google Scholar] [CrossRef] [PubMed]
- Mogensen, T.H.; Paludan, S.R. Molecular pathways in virus-induced cytokine production. Microbiol. Mol. Biol. Rev. 2001, 65, 131–150. [Google Scholar] [CrossRef] [PubMed]
- Castano-Rodriguez, N.; Kaakoush, N.O.; Mitchell, H.M. Pattern-recognition receptors and gastric cancer. Front. Immunol. 2014, 5. [Google Scholar] [CrossRef]
- Cheon, H.; Borden, E.C.; Stark, G.R. Interferons and their stimulated genes in the tumor microenvironment. Semin. Oncol. 2014, 41, 156–173. [Google Scholar] [CrossRef] [PubMed]
- Khodarev, N.N.; Roizman, B.; Weichselbaum, R.R. Molecular pathways: Interferon/stat1 pathway: Role in the tumor resistance to genotoxic stress and aggressive growth. Clin. Cancer Res. 2012, 18, 3015–3021. [Google Scholar] [CrossRef] [PubMed]
- Liu, Y.P.; Suksanpaisan, L.; Steele, M.B.; Russell, S.J.; Peng, K.W. Induction of antiviral genes by the tumor microenvironment confers resistance to virotherapy. Sci. Rep. 2013, 3. [Google Scholar] [CrossRef] [PubMed]
- Berchtold, S.; Lampe, J.; Weiland, T.; Smirnow, I.; Schleicher, S.; Handgretinger, R.; Kopp, H.G.; Reiser, J.; Stubenrauch, F.; Mayer, N.; et al. Innate immune defense defines susceptibility of sarcoma cells to measles vaccine virus-based oncolysis. J. Virol. 2013, 87, 3484–3501. [Google Scholar] [CrossRef] [PubMed]
- Echchgadda, I.; Chang, T.H.; Sabbah, A.; Bakri, I.; Ikeno, Y.; Hubbard, G.B.; Chatterjee, B.; Bose, S. Oncolytic targeting of androgen-sensitive prostate tumor by the respiratory syncytial virus (RSV): Consequences of deficient interferon-dependent antiviral defense. BMC Cancer 2011, 11. [Google Scholar] [CrossRef] [PubMed]
- Ruotsalainen, J.J.; Kaikkonen, M.U.; Niittykoski, M.; Martikainen, M.W.; Lemay, C.G.; Cox, J.; de Silva, N.S.; Kus, A.; Falls, T.J.; Diallo, J.S.; et al. Clonal variation in interferon response determines the outcome of oncolytic virotherapy in mouse CT26 colon carcinoma model. Gene Ther. 2015, 22, 65–75. [Google Scholar] [CrossRef] [PubMed]
- Monsurro, V.; Beghelli, S.; Wang, R.; Barbi, S.; Coin, S.; di Pasquale, G.; Bersani, S.; Castellucci, M.; Sorio, C.; Eleuteri, S.; et al. Anti-viral state segregates two molecular phenotypes of pancreatic adenocarcinoma: Potential relevance for adenoviral gene therapy. J. Transl. Med. 2010, 8. [Google Scholar] [CrossRef] [PubMed]
- Liikanen, I.; Monsurro, V.; Ahtiainen, L.; Raki, M.; Hakkarainen, T.; Diaconu, I.; Escutenaire, S.; Hemminki, O.; Dias, J.D.; Cerullo, V.; et al. Induction of interferon pathways mediates in vivo resistance to oncolytic adenovirus. Mol. Ther. 2011, 19, 1858–1866. [Google Scholar] [CrossRef] [PubMed]
- Qiao, J.; Wang, H.; Kottke, T.; White, C.; Twigger, K.; Diaz, R.M.; Thompson, J.; Selby, P.; de Bono, J.; Melcher, A.; et al. Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin. Cancer Res. 2008, 14, 259–269. [Google Scholar] [CrossRef] [PubMed]
- Bridle, B.W.; Clouthier, D.; Zhang, L.; Pol, J.; Chen, L.; Lichty, B.D.; Bramson, J.L.; Wan, Y. Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8 T-cell responses to anticancer vaccines. Oncoimmunology 2013, 2. [Google Scholar] [CrossRef] [PubMed]
- Ambar, B.B.; Frei, K.; Malipiero, U.; Morelli, A.E.; Castro, M.G.; Lowenstein, P.R.; Fontana, A. Treatment of experimental glioma by administration of adenoviral vectors expressing Fas ligand. Hum. Gene Ther. 1999, 10, 1641–1648. [Google Scholar] [CrossRef] [PubMed]
- Cho, H.I.; Jung, S.H.; Sohn, H.J.; Celis, E.; Kim, T.G. An optimized peptide vaccine strategy capable of inducing multivalent CD8 T cell responses with potent antitumor effects. Oncoimmunology 2015, 4. [Google Scholar] [CrossRef] [PubMed]
- Germano, G.; Frapolli, R.; Belgiovine, C.; Anselmo, A.; Pesce, S.; Liguori, M.; Erba, E.; Uboldi, S.; Zucchetti, M.; Pasqualini, F.; et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 2013, 23, 249–262. [Google Scholar] [CrossRef] [PubMed]
- Woller, N.; Gurlevik, E.; Fleischmann-Mundt, B.; Schumacher, A.; Knocke, S.; Kloos, A.M.; Saborowski, M.; Geffers, R.; Manns, M.P.; Wirth, T.C.; et al. Viral infection of tumors overcomes resistance to PD-1-immunotherapy by broadening neoantigenome-directed T-cell responses. Mol. Ther. 2015, 23, 1630–1640. [Google Scholar] [CrossRef] [PubMed]
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Cassady, K.A.; Haworth, K.B.; Jackson, J.; Markert, J.M.; Cripe, T.P. To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses. Viruses 2016, 8, 43. https://doi.org/10.3390/v8020043
Cassady KA, Haworth KB, Jackson J, Markert JM, Cripe TP. To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses. Viruses. 2016; 8(2):43. https://doi.org/10.3390/v8020043
Chicago/Turabian StyleCassady, Kevin A., Kellie B. Haworth, Josh Jackson, James M. Markert, and Timothy P. Cripe. 2016. "To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses" Viruses 8, no. 2: 43. https://doi.org/10.3390/v8020043